Telix revenue rose 19% year over year to US$245 million in the third quarter of 2026, driven by its prostate cancer imaging products. In its October 21 update, the radiopharmaceutical company reaffirmed expectations for full-year revenue and other income above US$1 billion, although quarterly revenue was slightly below the preceding quarter.
Key Takeaways
- Precision Medicine revenue rose 30% year over year to US$201 million, led by Gozellix and Illuccix.
- Telix narrowed its 2026 research and development spending guidance to US$240 million–US$260 million.
- Pixclara entered commercial use in September, while the proposed ITM merger remains subject to shareholder approval.
Table of Contents
- Telix revenue growth contrasts with a softer quarterly comparison
- Full-year outlook holds as R&D range narrows
- Pixclara launch expands the commercial portfolio
- ITM merger awaits shareholder decision
- Conclusion
Telix revenue growth contrasts with a softer quarterly comparison
The unaudited results for the quarter ended September 30 showed continued annual growth in the imaging business, offset partly by lower third-party revenue at Telix Manufacturing Solutions. Group revenue was down 1% from the second quarter.
Telix’s third-quarter financial update showed Precision Medicine revenue broadly unchanged from the preceding quarter. Chief Executive Christian Behrenbruch said U.S. dose volumes for Gozellix and Illuccix increased 1% quarter over quarter, reflecting expected summer seasonality.
Management said stronger September sales supported its confidence in delivering more than 25% Precision Medicine revenue growth for 2026. That remains a full-year expectation rather than a completed result.
| Item | Details |
|---|---|
| Group revenue | Q3 2026: US$245 million; Q3 2025: US$206 million; Q2 2026: US$247 million. |
| Precision Medicine revenue | Q3 2026: US$201 million; Q3 2025: US$155 million; Q2 2026: US$202 million. |
| Manufacturing Solutions third-party revenue | Q3 2026: US$44 million; Q3 2025: US$47 million; Q2 2026: US$45 million. Excludes Illuccix and Gozellix sales and inter-segment revenue. |
Full-year outlook holds as R&D range narrows
Telix said revenue was tracking toward the upper end of its US$950 million–US$970 million guidance range. Together with US$40 million of other income, the company expects the combined total to exceed US$1 billion.
The revenue outlook covers products in markets where marketing authorization has been granted, includes a full-year contribution from RLS Radiopharmacies and incorporates anticipated Pixclara sales.
Research and development expenditure is now expected to total US$240 million–US$260 million, compared with the previous US$230 million–US$270 million range. The revision narrows the range without changing its US$250 million midpoint, and remains subject to planned clinical, regulatory and development milestones.
Pixclara launch expands the commercial portfolio
The U.S. Food and Drug Administration approved Pixclara for glioma imaging during the quarter, and the first commercial doses were administered in September 2026. The launch adds brain cancer imaging to a commercial portfolio anchored by prostate cancer diagnostics.
Telix also completed enrollment of 350 patients in BiPASS, a Phase 3 study evaluating prostate cancer detection before biopsy using PET imaging alongside MRI. The FDA supported a new drug application pathway and granted Fast Track designation, which may enable expedited review but does not constitute approval.
For kidney cancer imaging candidate Zircaix, Telix was finalizing a regulatory resubmission addressing remaining third-party manufacturing observations. The company said submission to the FDA was planned in the near term and remained a priority for 2026.
In its therapeutic pipeline, the Phase 2 OPTIMAL-PSMA study of TLX597-Tx completed enrollment of 120 patients. Results are expected in the first half of 2027.
ITM merger awaits shareholder decision
The proposed merger with Isotope Technologies Munich would add therapeutic candidates and isotope production capabilities. Upfront consideration is US$1.65 billion on a cash-free, debt-free basis, with ITM shareholders expected to receive approximately US$1.25 billion in Telix shares issued as American depositary receipts.
A further payment of up to US$700 million is contingent on future regulatory approvals and commercial sales milestones for ITM-11, a treatment candidate for gastroenteropancreatic neuroendocrine tumors.
The transaction has not closed. It remains subject to Telix shareholder approval and customary closing conditions, with a general meeting expected on December 1, 2026, Australian Eastern Daylight Time.
Conclusion
The next scheduled corporate milestone is the shareholder meeting expected on December 1 to consider the ITM transaction. Telix also plans a near-term Zircaix resubmission, while its full-year outlook depends on continued commercial sales and execution of development milestones.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
